NCT01535859View on ClinicalTrials.gov

Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers

PHASE3CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2016

Conditions
Ovarian Hyperstimulation Syndrome
Interventions
DRUG

Cabergoline

Cabergoline in 0.5mg tablet. 1 tablet daily for 8 days.

DRUG

Placebo

1 tablet daily for 8 days.

Trial Locations (1)

229899

KK Women's and Children's Hospital, Singapore

All Listed Sponsors
lead

KK Women's and Children's Hospital

OTHER_GOV

NCT01535859 - Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers | Biotech Hunter | Biotech Hunter